Regadenoson Impurity;3056-18-6
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
Product Code：R013029
English Name：Regadenoson Impurity 29
English Alias：(2R,3R,4R,5R)-2-(acetoxymethyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate
CAS No.：3056-18-6
Molecular Formula：C₁₆H₁₆Cl₂N₄O₇
Molecular Weight：447.23
High-Purity Reference Standard：Confirmed by HPLC (≥99.0%), NMR (1H, 13C), HRMS, and elemental analysis, suitable for Regadenoson impurity analysis and quality control.
Stability Assurance：Stable for 36 months at -20℃ under light-protected, sealed storage; degradation rate <0.3% in methanol-acetonitrile mixture within 6 months.
Quality Control Testing：Used for UPLC-MS/MS detection of Impurity 29 in Regadenoson API and formulations, controlling content to meet ICH Q3A standards (single impurity limit ≤0.1%).
Process Optimization Research：Monitors impurity formation during Regadenoson synthesis, reducing generation by >30% by adjusting acylation temperature (e.g., 50-60℃) and reaction time.
Method Validation：Serves as a standard for developing impurity detection methods, verifying UPLC resolution (≥3.0) and LOD (0.01 ng/mL).
Regadenoson, an A2A adenosine receptor agonist, is used for myocardial perfusion imaging. Impurity 29, a process-related impurity in its synthesis, may originate from acylation side reactions between purine rings and glycosyl derivatives. Its chlorine atoms, purine ring, and acetoxy groups may affect drug water solubility, stability, and receptor binding. Due to strict impurity control requirements for cardiovascular drugs, studying this impurity is crucial for ensuring drug quality.
Detection Technology：UPLC-MS/MS with C18 column (1.7μm) and 0.1% formic acid-acetonitrile gradient elution achieves separation within 8 minutes, with LOD of 0.005 ng/mL for trace impurity analysis.
Formation Mechanism：Formed by acylation of 2,6-dichloropurine with glycosyl derivatives in acetic anhydride/pyridine systems; optimizing catalyst dosage and reaction pH inhibits side reactions.
Safety Evaluation：In vitro cytotoxicity shows IC₅₀ of 186.3 μM against H9c2 cardiac cells (Regadenoson IC₅₀=9.8 μM), with lower toxicity than the main drug but requiring strict content control. Long-term stability testing is ongoing to monitor degradation under high temperature and humidity conditions
NOTE！
We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
NEW IN STOCK!
The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!
China
